Horizon Investments LLC trimmed its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 47.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,917 shares of the company's stock after selling 24,641 shares during the period. Horizon Investments LLC's holdings in Kenvue were worth $575,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Grove Bank & Trust boosted its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after buying an additional 1,441 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
KVUE has been the topic of several analyst reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Barclays lowered their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and cut their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. Finally, UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $23.85.
Get Our Latest Stock Report on KVUE
Kenvue Stock Down 1.2 %
Shares of Kenvue stock traded down $0.29 during trading on Tuesday, hitting $23.08. The company's stock had a trading volume of 14,987,646 shares, compared to its average volume of 16,155,267. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market capitalization of $44.11 billion, a PE ratio of 43.55, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a fifty day simple moving average of $22.13 and a two-hundred day simple moving average of $22.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
